Chronic Stable Angina – Pipeline Review, 2019

Angina is used to refer to the pain, discomfort or pressure in the chest. Heart arteries which are blocked cause chest pain (angina), because there are areas of the heart who do not get enough oxygen. The most common types of angina: chronic stable angina and unstable angina. In chronic stable angina, the chest pain occurs when the heart is working hard to get enough oxygen such as in during exercise. The pattern of this pain, such as the longevity of the pain, how often it occurs, what triggers it and its response to the treatment options, makes its stable for at least two months.

The treatment of chronic stable angina depends on angina and a number of other factors. If the angina is of a stable nature, it can be controlled with lifestyle changes and medications. Some of the medications for the treatment of chronic stable angina include aspirin, nitrates, beta blockers, statin, ranolazine (ranexa), and calcium channel blockers.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for chronic stable angina. For instance; T89, which is being studied by Tasly Pharmaceuticals, Inc., is currently in phase-2 clinical trials for the outcome research to confirm the anti-anginal effect of T89 in patients with stable angina.

At present around 70% of the pipeline candidates for Chronic Stable Angina are in the phase-2 and phase-4 stage combined. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Chronic Stable Angina – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Chronic Stable Angina. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Chronic Stable Angina.

The report on ‘Chronic Stable Angina – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Chronic Stable Angina


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Chronic Stable Angina


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary